Bristol-Myers Squibb Cash Flow Statement
NYSE: BMYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Bristol-Myers Squibb free cash flow
In fiscal 2025, Bristol-Myers Squibb generated $14.16 billion of operating cash flow and spent $1.31 billion on capital expenditures. That left free cash flow of $12.85 billion, a free-cash-flow margin of 26.7% of revenue. Free cash flow was down 7.9% from the prior year's $13.94 billion.
Bristol-Myers Squibb returned $5.04 billion to shareholders through dividends, equal to 39% of free cash flow. Free cash flow covered dividend payments 2.5 times.
Summary generated from market data by MetaCap's automated system. Methodology
Bristol-Myers Squibb cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 7.05B | -8.93B | 8.04B | 6.34B | 7.01B | -8.99B | 3.46B | 4.95B | 975.00M | 4.51B |
| Net Income growth (YoY) | — | -211.11% | +26.71% | -9.54% | — | -359.97% | -30.06% | +407.38% | -78.37% | +176.33% |
| Depreciation & Amortization | 4.01B | 9.60B | 9.76B | 10.28B | 10.69B | 10.38B | 1.75B | 637.00M | 789.00M | 382.00M |
| Stock-Based Compensation | 553.00M | 507.00M | 518.00M | 457.00M | 583.00M | 779.00M | 441.00M | 221.00M | 199.00M | 205.00M |
| Change in Working Capital | -481.00M | -38.00M | -1.55B | -623.00M | -796.00M | 2.21B | 1.44B | -704.00M | -140.00M | -851.00M |
| Operating Cash Flow | 14.16B | 15.19B | 13.86B | 13.07B | 16.21B | 14.05B | 8.21B | 7.07B | 5.28B | 3.06B |
| Capital Expenditures | -1.31B | -1.25B | -1.21B | -1.12B | -973.00M | -753.00M | -836.00M | -951.00M | -1.05B | -1.22B |
| Investing Cash Flow | -4.13B | -21.35B | -2.29B | -1.06B | -538.00M | -10.86B | -9.91B | -2.00B | -66.00M | 1.48B |
| Dividends Paid | -5.04B | -4.86B | -4.74B | -4.63B | -4.40B | -4.08B | -2.68B | -2.61B | -2.58B | -2.55B |
| Share Repurchases | 0 | 0 | -5.16B | -8.00B | -6.29B | -1.55B | -7.30B | -320.00M | -2.47B | -231.00M |
| Debt Issued | 5.74B | 12.88B | 4.46B | 5.93B | 0 | 6.95B | 26.78B | 0 | 1.49B | 0 |
| Debt Repaid | -10.94B | -2.87B | -3.88B | -11.43B | -6.02B | -2.75B | -9.26B | -5.00M | -1.22B | -15.00M |
| Financing Cash Flow | -10.35B | 5.13B | -9.42B | -16.96B | -16.22B | -1.15B | 7.62B | -3.54B | -4.08B | -2.65B |
| Net Change in Cash | -129.00M | -1.17B | 2.19B | -4.99B | -657.00M | 2.15B | 5.91B | 1.49B | 1.18B | 1.85B |
| Free Cash Flow | 12.85B | 13.94B | 12.65B | 11.95B | 15.23B | 13.30B | 7.37B | 6.12B | 4.22B | 1.84B |
This table shows 10 annual periods of Bristol-Myers Squibb's cash flow statement, from FY 2025 back to FY 2016, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BMY's reporting calendar. What is a cash flow statement?